The latest data point for PFE's P/E Ratio in Q1'26 stands at 14.70, reflecting a moderate valuation level following a slight decline from the previous quarter's 19.83 in Q4'25. Over the period from Q2'23 to Q1'26, the P/E Ratio exhibits high volatility, starting at 9.42 in Q2'23 and rising sharply to 73.42 in Q4'23 before plunging into negative territory with -518.43 in Q1'24 and -64.94 in Q2'24, likely indicating earnings challenges or accounting adjustments. It then rebounded to positive values, peaking at 37.00 in Q3'24, and has since stabilized in the 13-20 range from Q1'25 onward, suggesting improving but still fluctuating investor sentiment toward Pfizer's earnings outlook.